Q-omics provides the consensus-scored GUCY1A2 profile across patient tissues and cancer cell-line models. GUCY1A2 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, GUCY1A2 is differentially expressed in 9, with the highest sampling consensus in LUSC. Additionally, GUCY1A2 protein abundance shows 27,540 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight UVM, LUSC, and LSCC as cancer lineages where GUCY1A2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GUCY1A2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GUCY1A2 survival associations across molecular data types. GUCY1A2 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (7) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GUCY1A2 RNA expression–survival associations across cancer types. High GUCY1A2 expression shows unfavorable associations in UVM, STAD, KIRP, BLCA and MESO, but favorable associations in KIRC. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for GUCY1A2 RNA expression.
This table summarizes GUCY1A2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 9, while mass-spec protein shows differences in 5. The strongest signals are observed in LUSC for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for GUCY1A2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GUCY1A2 shows lower tumor expression in LUSC, LUAD and UCEC and higher tumor expression in HNSC, STAD and KIRC. The LUSC box plot shows higher GUCY1A2 RNA expression in normal versus tumor tissue (log2 FC = −2.355, t-test p < 0.001).
This table shows molecular features associated with GUCY1A2 in patient tissues and cancer cell lines. In patient samples, GUCY1A2 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, GUCY1A2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in KIDNEY, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia and LARGE_INTESTINE.
